Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 20/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6978467 | 0.93 | CXCR2 (1.00) | CXCR2 | |
| SCHEMBL6982641 | 0.90 | CXCR2 (0.71) | CXCR2 | |
| SCHEMBL6968889 | 0.89 | CXCR2 (0.70) | CXCR2 | |
| SCHEMBL6978362 | 0.89 | CXCR2 (0.70) | CXCR2 | |
| SCHEMBL6980327 | 0.87 | CXCR2 (0.67) | CXCR2 | |
| SCHEMBL6980147 | 0.87 | CXCR2 (0.70) | CXCR2 | |
| SCHEMBL6978091 | 0.86 | CXCR2 (0.70) | CXCR2 | |
| SCHEMBL6982416 | 0.86 | CXCR2 (0.94) | CXCR2 | |
| SCHEMBL6976433 | 0.86 | CXCR2 (0.78) | CXCR2 | |
| SCHEMBL6979327 | 0.85 | CXCR2 (1.00) | CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1109790-B1 | 1, 2, 4-TRIAZOLE-3-THIONE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-05-14 | — | — | EP | claimed |
| US-20020086862-A1 | Novel compounds | ASTRAZENECA AB | 2002-07-04 | — | — | US | claimed |
| EP-1109790-A1 | 1, 2, 4-TRIAZOLE-3-THIONE COMPOUNDS | AstraZeneca AB (SE) | 2001-06-27 | — | — | EP | claimed |
| WO-2000012489-A1 | 1, 2, 4-TRIAZOLE-3-THIONE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-03-09 | — | — | WO | claimed |
| EP-1109790-B1 | 1, 2, 4-TRIAZOLE-3-THIONE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-05-14 | — | — | EP | disclosed |
| US-20020086862-A1 | Novel compounds | ASTRAZENECA AB | 2002-07-04 | — | — | US | disclosed |
| EP-1109790-A1 | 1, 2, 4-TRIAZOLE-3-THIONE COMPOUNDS | AstraZeneca AB (SE) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000012489-A1 | 1, 2, 4-TRIAZOLE-3-THIONE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086862-A1 | Novel compounds | ABCG2, CYP3A4, CYP4B1 | CXCR2 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.